Australia's Lumos Diagnostics soars most in two years on US distribution agreement

Lumos Diagnostics Holdings

16/07/2025 02:21

** Shares of Lumos Diagnostics LDX.AX more than double in value to A$0.080

** Stock posts its biggest intraday pct gain since July 2023

** Healthcare tech co signs U.S. distribution and supply agreement for FebriDx valued at up to $317 million

** FebriDx is a rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a fingerstick blood sample

** Agreement signed with Hong Kong-headquartered PHASE Scientific International

** About 15.8 million shares change hands, compared with the 30-day average volume of 663,247

** YTD, shares up 108.6%

 (Reporting by Nichiket Sunil in Bengaluru)

 ((Nichiket.Sunil@thomsonreuters.com;))